Skip to main content
SpringerLink
Log in

Fall 66: Therapie – 57 Jahre, ♂, DM Typ 2, koronare Herzerkrankung

  • Chapter
  • First Online:
Diabetes-Therapie – informiert entscheiden

  • 2271 Accesses

Zusammenfassung

Ein 57-jähriger Patient mit koronarer Herzerkrankung und einem Diabetes Typ 2 seit 8 Jahren ist mit Glibenclamid und Metformin auf einem HbA1c von 6,8 eingestellt. Soll die Medikation so belassen werden?

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 29.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH, Lange T, Abildstrom SZ, Schramm TK, Vaag A, Kober L, Torp-Pedersen C, HGG (2010) Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 53(12):2546–2553

    Article  CAS  Google Scholar 

  • Bundesärztekammer (BÄK) KBK, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2014) Therapie des Typ-2-Diabetes – Leitlinien-Report. Nationale VersorgungsLeitlinie 1. Auflage (Version 3. 2014, zuletzt verändert: Februar 2015). https://doi.org/10.6101/azq/000226

  • Evans JM, Ogston SA, Emslie-Smith A, DMA (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49(5):930–936

    Google Scholar 

  • Forst T, Hanefeld M, Jacob S, Moeser G, Schwenk G, Pfützner A, AH (2013) Association of sulfonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res 10(4):302–314

    Article  CAS  Google Scholar 

  • Jorgensen CH, Gislason GH, Andersson C, Ahlehoff O, Charlot M, Schramm TK, Vaag A, Abildstrom SZ, Torp-Pedersen C, RHP (2010) Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention–a retrospective nationwide cohort study. Cardiovasc Diabetol 9(54)

    Google Scholar 

  • Lamanna C, Monami M, Marchionni N, EM (2011) Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13(3):221–228

    Article  CAS  Google Scholar 

  • Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, SZR (2010) The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 33(6):1224–1229

    Article  CAS  Google Scholar 

  • Rao AD, Kuhadiya N, Reynolds K, AFV (2008) Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 31(8):1672–1678

    Article  Google Scholar 

  • Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbol EL, Kober L, Norgaard ML, Madsen M, Hansen PR, CT-P (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32(15):1900–1908

    Google Scholar 

  • Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, PE (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339(-):b4731

    Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998a) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131):854–865

    Article  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998b) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853

    Article  Google Scholar 

  • Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, Berland J, Gueret P, Wyart P, Deturck R, Tabone X, Machecourt J, Leclercq F, Drouet E, Mulak G, Bataille V, Cambou JP, Ferrieres J, TS (2010) Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 95(11):4993–5002

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Innere Medizin I, Medizinische Universitätsklinik, Heidelberg, Deutschland

    Alba Sulaj

Authors
  1. Alba Sulaj
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alba Sulaj .

Editor information

Editors and Affiliations

  1. Abteilung Innere Medizin I, Medizinische Universitätsklinik, Heidelberg, Germany

    Lars Kihm

  2. Abteilung Innere Medizin I, Medizinische Universitätsklinik, Heidelberg, Germany

    Stefan Kopf

  3. Zentrum für Innere Medizin I und klinische Chemie, Medizinische Universitätsklinik, Heidelberg, Germany

    Peter Nawroth

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sulaj, A. (2018). Fall 66: Therapie – 57 Jahre, ♂, DM Typ 2, koronare Herzerkrankung. In: Kihm, L., Kopf, S., Nawroth, P. (eds) Diabetes-Therapie – informiert entscheiden. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-55972-7_66

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-55972-7_66

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-55971-0

  • Online ISBN: 978-3-662-55972-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation